Explore

Trendline Trendline
Intellia Therapeutics Advances CRISPR Gene Editing with FDA Application for Hereditary Angioedema Treatment

Intellia Therapeutics Advances CRISPR Gene Editing with FDA Application for Hereditary Angioedema Treatment

Intellia Therapeutics Advances CRISPR Gene Editing with FDA Application for Hereditary Angioedema Treatment
Trendline Trendline
RIVANNA Secures FDA Clearance for Accuro XV Ultrasound System, Enhancing Musculoskeletal Imaging

RIVANNA Secures FDA Clearance for Accuro XV Ultrasound System, Enhancing Musculoskeletal Imaging

RIVANNA Secures FDA Clearance for Accuro XV Ultrasound System, Enhancing Musculoskeletal Imaging
Trendline Trendline
Incyte Releases Positive Long-Term Data for Opzelura Cream in Atopic Dermatitis Treatment

Incyte Releases Positive Long-Term Data for Opzelura Cream in Atopic Dermatitis Treatment

Incyte Releases Positive Long-Term Data for Opzelura Cream in Atopic Dermatitis Treatment
Trendline Trendline
Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion

Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion

Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion
Trendline Trendline
Scholar Rock Advances Apitegromab for SMA with FDA Approval Milestone

Scholar Rock Advances Apitegromab for SMA with FDA Approval Milestone

Scholar Rock Advances Apitegromab for SMA with FDA Approval Milestone
Trendline Trendline
Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics for Enzyme Therapy Development

Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics for Enzyme Therapy Development

Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics for Enzyme Therapy Development
Trendline Trendline
Harbour BioMed Receives FDA Clearance for HBM7004 to Treat Advanced Solid Tumors

Harbour BioMed Receives FDA Clearance for HBM7004 to Treat Advanced Solid Tumors

Harbour BioMed Receives FDA Clearance for HBM7004 to Treat Advanced Solid Tumors
Trendline Trendline
Lilly Invests $4.5 Billion in Indiana Manufacturing, Opens Genetic Medicine Site

Lilly Invests $4.5 Billion in Indiana Manufacturing, Opens Genetic Medicine Site

Lilly Invests $4.5 Billion in Indiana Manufacturing, Opens Genetic Medicine Site
Trendline Trendline
Niagen Bioscience to Participate in May 2026 Investor Conferences Highlighting NAD+ Research

Niagen Bioscience to Participate in May 2026 Investor Conferences Highlighting NAD+ Research

Niagen Bioscience to Participate in May 2026 Investor Conferences Highlighting NAD+ Research
Trendline Trendline
Personalized Medicine Market Projected to Reach USD 1,397.63 Billion by 2035 Due to Genomic Advancements

Personalized Medicine Market Projected to Reach USD 1,397.63 Billion by 2035 Due to Genomic Advancements

Personalized Medicine Market Projected to Reach USD 1,397.63 Billion by 2035 Due to Genomic Advancements
Trendline Trendline
ISOThrive Announces Positive Phase 2 Results for MHS-1031 in NERD Patients

ISOThrive Announces Positive Phase 2 Results for MHS-1031 in NERD Patients

ISOThrive Announces Positive Phase 2 Results for MHS-1031 in NERD Patients
Trendline Trendline
UnitedHealthcare to Eliminate 30% of Prior Authorization Requirements by 2026

UnitedHealthcare to Eliminate 30% of Prior Authorization Requirements by 2026

UnitedHealthcare to Eliminate 30% of Prior Authorization Requirements by 2026